JonBlairChickMD

PubMed

• First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.
  Yap TA, Arkenau H, Camidge DR, George S, Serkova NJ, Gwyther SJ, Spratlin JL, Lal R, Spicer J, Desouza NM, Leach MO, Chick J, Poondru S, Boinpally R, Gedrich R, Brock ...> ;Clin. Cancer Res.. 2013-02-15
• Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.
  Hughes, A. N., O'Brien, M. E., Petty, W. J., Chick, J. B., Rankin, E., Woll, P. J., Dunlop, D., Nicolson, M., Boinpally, R., Wolf, J., Price, A.> ;J Clin Oncol. 2009 Mar 10
• Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
  Ricart, A. D., Berlin, J. D., Papadopoulos, K. P., Syed, S., Drolet, D. W., Quaratino-Baker, C., Horan, J., Chick, J., Vermeulen, W., Tolcher, A. W., Rowinsky, E. K., ...> ;Clin Cancer Res. 2008 Dec 01
• A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer.
  Clamp, A. R., Schöffski, P., Valle, J. W., Wilson, R. H., Marreaud, S., Govaerts, A. S., Debois, M., Lacombe, D., Twelves, C., Chick, J., Jayson, G. C.> ;Cancer Chemother Pharmacol. 2008 Apr
• A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers.
  Ciuleanu, T., Diculescu, M., Hoepffner, N. M., Trojan, J., Sailer, V., Zalupski, M., Herrmann, T., Roth, A., Chick, J., Brock, K., Albert, D., Philip, P. A.> ;Invest New Drugs. 2007 Aug
• Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenoca...
  Falk, S., Anthoney, A., Eatock, M., Van Cutsem, E., Chick, J., Glen, H., Valle, J. W., Drolet, D. W., Albert, D., Ferry, D., Ajani, J.> ;Br J Cancer. 2006 Aug 21
• A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies.
  Lee, C.P., de Jonge, M.A., O'Donnell, A.E., Schothorst, K.L., Hanwell, J., Chick, J.B., Brooimans, R.A., Adams, L.M., Drolet, D.W., de Bono, J.S., Kaye, S.B., Judson, ...> ;Clin Cancer Res. 2006 May 1
• Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.
  Beutel, G., Glen, H., Schöffski, P., Chick, J., Gill, S., Cassidy, J., Twelves, C.> ;Clin Cancer Res. 2005 Aug 1
• A phase II study of single agent paclitaxel in patients at first relapse following initial chemotherapy for breast cancer.
  Davidson, N. G., Chick, J. B., Perren, T. J., Campbell, N., Thompson, J. M., Chan, Y. T.> ;Clin Oncol (R Coll Radiol). 1996
• Join now to see all